Kenny Workman

Edwin H. Wintermute, Harmon Bhasin, Christina M. Agapakis et al.

As AI agents are incorporated into life science workflows, the capabilities that speed discovery might also enable misuse. We present BioSecBench-Refusal, a benchmark for risk identification and refusal behavior for biological research tasks. The benchmark pairs 61 Routine tasks, legitimate analyses adapted from the published literature, with 46 Red-Team tasks, fictional scenarios that resemble real research but conceal a biosecurity hazard. Across 16 model-harness configurations, refusal rates ranged from 7\% to 74\% on Routine tasks and 1\% to 62\% on Red-Team tasks, with many configurations refusing legitimate Routine work at comparable or higher rates than concealed hazards. Refusals were most often triggered by provider API filters applied prior to agentic reasoning. However, models given room to reason showed the potential to identify more real threats. We release BioSecBench-Refusal as a tool for model developers to calibrate capability and caution for agentic biotech R\&D.

Kenny Workman, Zhen Yang, Harihara Muralidharan et al.

Spatial transcriptomics assays are rapidly increasing in scale and complexity, making computational analysis a major bottleneck in biological discovery. Although frontier AI agents have improved dramatically at software engineering and general data analysis, it remains unclear whether they can extract biological insight from messy, real-world spatial datasets. We introduce SpatialBench, a benchmark of 146 verifiable problems derived from practical spatial analysis workflows spanning five spatial technologies and seven task categories. Each problem provides a snapshot of experimental data immediately prior to an analysis step and a deterministic grader that evaluates recovery of a key biological result. Benchmark data on frontier models shows that base model accuracy remains low (20-38% across model families), with strong model-task and model-platform interactions. Harness design has a large empirical effect on performance, indicating that tools, prompts, control flow, and execution environment should be evaluated and improved as first-class objects. SpatialBench serves both as a measurement tool and a diagnostic lens for developing agents that can interact with real spatial datasets faithfully, transparently, and reproducibly.

Ian Diks, Zhen Yang, Arjun Banerjee et al.

Single-cell studies require analysts to convert raw measurements into specific biological claims through multi-step workflows and integration of metadata, assay context, and auxiliary evidence. Existing AI-biology benchmarks largely measure broad knowledge, executable workflows, or local analysis steps. We introduce scBench-Long, a benchmark for long-horizon single-cell biology in which agents must recover scientific conclusions from raw or near-raw data without prescribed methods. The benchmark contains 21 evaluations spanning melanoma CD8 T-cell reactivity, CD8 RNA+ATAC regulatory inference, human--monkey chimera development, KRAS-driven lung tumor aging, and lethal COVID-19 lung pathology. Tasks cover paired scRNA/TCR sequencing, RNA and chromatin profiling, cross-species transcriptomics, combinatorial scRNA-seq, single-nucleus RNA-seq, immune repertoires, ortholog maps, ligand--receptor resources, and validation evidence. Candidate claims are reproduced, reviewed, and converted into controlled answer vocabularies with deterministic grading and trajectory rubrics. Across 1,068 completed trajectories, the strongest model--harness pair passes 16/63 runs (25.4\%). scBench-Long evaluates whether agents can move beyond local analysis steps and make complex scientific claims that are supported by single-cell data.

Ian Diks, Harihara Muralidharan, Tim Proctor et al.

AI agents are increasingly useful for biological data analysis, but existing benchmarks mostly test broad biological knowledge, executable workflows, or localized analysis steps rather than end-to-end scientific reasoning over spatial measurements. We introduce SpatialBench-Long, a benchmark for long-horizon spatial biology in which agents must recover biological claims from raw or near-raw data and calibrated experimental context without prescribed methods. SpatialBench-Long contains 24 evaluations across primary pancreatic ductal adenocarcinoma (PDAC), engineered glioblastoma organoids and in vivo tumors, Cas9 lineage-traced lung adenocarcinoma, and mouse optic nerve aging/intervention systems, spanning CosMx, Visium, Xenium, multiplexed error-robust fluorescence in situ hybridization (MERFISH), single-cell RNA sequencing (scRNA-seq), Slide-seq, Slide-tags, histology, and lineage-recording data. Candidate claims are hardened through reproduction, independent scientist review, and trajectory inspection. Final answers are graded deterministically over controlled vocabularies and symbols with companion rubrics capturing progress through key analysis chokepoints. Across the SpatialBench-Long benchmark, three model-harness pairs tie at 8/72 runs (11.1\%): Gemini 3.5 Flash / Pi terminal coding harness, GPT-5.5 / Pi, and GPT-5.5 / OpenAI Codex. SpatialBench-Long tests whether agents can move beyond executing procedural analysis to deriving accurate scientific conclusions from complex spatial measurements.

Hannah Le, Ramesh Ramasamy, Alex Urrutia et al.

Artificial intelligence (AI) agents promise to accelerate drug discovery by compressing interpretation and decision-making loops, but practical deployment requires trusted evaluation on realistic program decisions. We introduce TherapeuticsBench Preclinical Pharmacology (TxBench-PP), a verifiable benchmark for small-molecule preclinical pharmacology and the first focused slice of a broader TherapeuticsBench effort across drug-discovery stages and therapeutic modalities. TxBench-PP tests whether agents can recover accurate conclusions from real-world assay data rather than memorized facts from literature. The benchmark contains 100 evaluations indexed by program stage, assay type, and task structure, spanning mechanism-of-action (MoA) and pharmacodynamic (PD) reasoning, compound-target engagement, causal target validation, developability and safety, and translational efficacy. Agents receive realistic workflow snapshots, inspect files in a coding environment, and return structured answers graded deterministically. Across 16 model-harness configurations, comprising 11 models and 4,800 trajectories, no system reliably recovered preclinical pharmacology decisions. The strongest configuration, Claude Opus 4.8 / Pi, passed 59.3\% of endpoint attempts (178/300; 95\% CI, 51.1-67.6), followed by GPT-5.5 / Pi at 55.3\% (166/300; 47.0-63.6).

Harihara Muralidharan, Reema Baskar, Soo Hee Lee et al.

We introduce EpiBench, a verifiable benchmark for short-horizon epigenomics analysis. EpiBench evaluates whether agents can make well-defined analysis decisions from realistic workflow states and return deterministically gradable answers. The benchmark includes 106 evaluations across CUT\&Tag/CUT\&RUN, ATAC-seq, ChIP-seq, and DNA methylation workflows. Across 5,088 valid trajectories from 16 model-harness pairs, no system passed a majority of attempts: GPT-5.5 / Pi led at 45.0\% (143/318 attempts; 95\% confidence interval (CI), 36.3--53.7), followed by GPT-5.5 / OpenAI Codex at 39.9\% (127/318 attempts; 95\% CI, 31.6--48.3). Claude Opus 4.8 Max / Pi and GPT-5.4 / Pi each passed 39.0\% (124/318 attempts; 95\% CI, 30.2--47.8 and 31.0--47.0, respectively). Performance varies across assay types, and many failed runs still contain parts of the correct answer. Agents often found the right files and computed useful intermediate results, but failed when the task required deeper, assay-specific scientific judgment.

Kenny Workman, Zhen Yang, Harihara Muralidharan et al.

As single-cell RNA sequencing datasets grow in adoption, scale, and complexity, data analysis remains a bottleneck for many research groups. Although frontier AI agents have improved dramatically at software engineering and general data analysis, it remains unclear whether they can extract biological insight from messy, real-world single-cell datasets. We introduce scBench, a benchmark of 394 verifiable problems derived from practical scRNA-seq workflows spanning six sequencing platforms and seven task categories. Each problem provides a snapshot of experimental data immediately prior to an analysis step and a deterministic grader that evaluates recovery of a key biological result. Benchmark data on eight frontier models shows that accuracy ranges from 29-53%, with strong model-task and model-platform interactions. Platform choice affects accuracy as much as model choice, with 40+ percentage point drops on less-documented technologies. scBench complements SpatialBench to cover the two dominant single-cell modalities, serving both as a measurement tool and a diagnostic lens for developing agents that can analyze real scRNA-seq datasets faithfully and reproducibly.